Trial Profile
IBCSG 25-02: A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (TEXT)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Triptorelin (Primary) ; Tamoxifen
- Indications Ductal carcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms TEXT
- 15 Dec 2022 Results (n=4690) assessing the 12-year SOFT-TEXT late treatment effects on distant recurrence-free interval and overall survival and benefits in women with human epidermal growth factor receptor 2 negative tumors and in those at high risk of disease relapse, published in the Journal of Clinical Oncology.
- 12 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2025.
- 04 Aug 2020 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.